Jimenez-Mora, Mario A et al. “Association of Overweight, Obesity and Abdominal Obesity with Socioeconomic Status and Educational Level in Colombia.” Diabetes, metabolic syndrome and obesity : targets and therapy vol. 13 1887-1898. 3 Jun. 2020, doi:10.2147/DMSO.S244761​

Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a disease: The Obesity Society 2018 position statement. Obesity (Silver Spring). 2019; 27: 7-9.

Información para prescribir a disposición del cuerpo médico en la Dirección Médica de Novo  Nordisk Colombia S.A.S., Calle 125 No. 19-24,Piso 6, Bogotá D.C., Colombia. Teléfono: 60-1-3149999. Correo electrónico electrónico:INFOMEDICACOL@novonordisk.com. 2. Fujioka K, O'Neil PM, Davies M, Greenway F, C W Lau D, Claudius B,- 1 (cont) -Skjøth TV, Bjørn Jensen C, P H Wilding J. Early Weight  Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 Nov;24(11):2278-2288.